The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).
 
Michael J. Morris
Consulting or Advisory Role - Astellas Pharma; Bayer; Millennium; Progenics
Research Funding - Agensys (Inst); Bayer (Inst); Janssen Oncology (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - fujifilm
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Honoraria - Astellas Pharma; Bayer; Bellicum Pharmaceuticals; Exelixis; Ferring; Genentech; Johnson & Johnson; Medivation; Merck Serono; Millennium; Pfizer; Progenics; Sanofi
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Astellas Medivation; Dendreon; Endocyte; Genentech; gtx; Johnson & Johnson; Merck; Millennium; Novartis; Oncogenex; Progenics; progenics; Sanofi
Expert Testimony - Celgene; sanofi
Travel, Accommodations, Expenses - Bayer; Bellicum Pharmaceuticals; Celgene; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Oncogenex; Pfizer; Progenics; Sanofi
 
A. Oliver Sartor
Consulting or Advisory Role - Algeta ASA; Aragon Pharmaceuticals; Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Biscayne Pharmaceuticals; Johnson & Johnson; Medivation; Oncogenex; Pfizer; Sanofi
Research Funding - Algeta ASA (Inst); Bayer (Inst); Johnson & Johnson (Inst); Progenics (Inst); Sanofi (Inst); Takeda (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Abbvie; Bavarian Nordic; Dava Oncology; Endocyte; Mannkind; UpToDate
Consulting or Advisory Role - Amgen; AVEO; BIND Biosciences; Cerulean Pharma; Janssen Biotech; Labceutics; Pfizer
Speakers' Bureau - Bayer; Caris MPI; Dendreon; Genentech/Roche; GlaxoSmithKline; Medivation; Millennium; Pfizer; Sanofi
Research Funding - Endocyte (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Parexel (Inst); Progenics (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Celgene; Dendreon; Exelixis; Genentech/Roche; Novartis; Pfizer; US Oncology
 
Michael Groaning
Stock and Other Ownership Interests - Endocyte
 
Samuel Ejadi
No Relationships to Disclose
 
Anthony W. Tolcher
Employment - START
Leadership - Symphony Evolution
Consulting or Advisory Role - Akebia Therapeutics; ArQule; Asana Biosciences; Astex Pharmaceuticals; Bayer Schering Pharma; Bind Therapeutics; Blend Therapeutics; Celator; Dicerna; Endocyte; Genmab; Heron; Janssen; Johnson & Johnson; Johnson & Johnson; Mersana; Merus; Nanobiotix; Pharmacyclics; Pierre Fabre; Proximagen; Symphony Evolution; Upsher-Smith; Valent Technologies
Research Funding - AbbVie (Inst); ArQule (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Cerulean Pharma (Inst); Dicerna (Inst); Endocyte (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Macrogenics (Inst); Pfizer (Inst); TaiRx, Inc. (Inst)
 
Hani M. Babiker
Research Funding - Endocyte (Inst)